Ajanta Pharma: Navigating Growth with Strategic Precision in Q3 FY26

Ajanta Pharma Limited, a prominent specialty pharmaceutical formulation company, has reported a robust performance for the third quarter and nine months ended December 31, 2025 (Q3 FY26). The company's consolidated revenue from operations surged by an impressive 20% year-on-year in Q3 FY26, reaching ₹1,375 crore, up from ₹1,146 crore in Q3 FY25. This strong top-line growth was complemented by a healthy 18% increase in Profit After Tax (PAT), which stood at ₹274 crore for the quarter. For the nine-month period, revenue grew by 16% to ₹4,031 crore, with PAT rising by 14% to ₹789 crore. Management expressed confidence in sustaining this growth momentum, highlighting that all businesses are broadly aligning with their plans.

Segmental Performance: A Mixed Yet Resilient Picture

Ajanta Pharma's diversified business model proved its resilience, with strong performances in key segments offsetting softer traction in others. The US Generics business emerged as a star performer, delivering an excellent 52% growth in Q3 FY26 and 46% for the nine-month period, with sales reaching ₹399 crore and ₹1,052 crore, respectively. This robust growth was attributed to eight new product launches over the last 12 months, consistent execution, and strong customer relationships. The India branded generic business also demonstrated healthy growth, with sales increasing by 19% in Q3 FY26 to ₹409 crore and by 15% for the nine-month period to ₹1,250 crore. This performance significantly outpaced the Indian pharmaceutical market (IPM) growth by 28%, with Ajanta achieving 11% growth compared to IPM's 9% as per IQVIA MAT December 2025.

However, the Asia branded generic business experienced a 9% degrowth in Q3 FY26, with sales at ₹288 crore, and a modest 1% growth for the nine-month period, reaching ₹902 crore. This was primarily due to softer-than-anticipated performance in a few markets and some delayed exports. Similarly, the Africa Institution business saw a moderate 6% degrowth for the nine-month period, with sales at ₹111 crore, mainly due to lower procurement by aid agencies. Despite these challenges, the overall branded generics segment grew by 11% in Q3 FY26 and 9% for the nine-month period, contributing 68% and 71% to the total revenue, respectively.

Strategic Initiatives and Future Outlook

Ajanta Pharma is actively pursuing several strategic initiatives to sustain its growth trajectory. A significant focus is on new product launches across markets, with 16 new products introduced in India and 7 in Africa during 9M FY26. The company is also making a strategic entry into the GLP-1 Semaglutide segment, with plans for an India launch under its own trademark by March and an overseas partnership with Biocon covering 26 countries. Revenues from the GLP-1 segment are anticipated to commence from FY27-28. Management expects competition in India for GLP-1 to be aggressive but less so in emerging markets.

To enhance market penetration, Ajanta Pharma expanded its field force, adding 150 medical representatives in Q3 FY26, bringing the total additions for the year to 300 and the overall MR strength to 3,750. The company is also exploring geographical expansion into new territories, with Latin America being a potential target. Furthermore, Ajanta Pharma is actively looking for strategic acquisitions, with over ₹1,000 crore potentially allocated for such opportunities, underscoring its commitment to inorganic growth.

Financial Health and Management Commentary

Ajanta Pharma maintains a strong financial position, with a gross margin of 79% for Q3 FY26 and 78% for the nine-month period. EBITDA margin stood at 28% for Q3 FY26 and 26% for 9M FY26. Excluding mark-to-market forex loss of ₹61 crore for 9M FY26, the adjusted EBITDA margin was 28%. The company's Return on Capital Employed (ROCE) was 34%, and Return on Net Worth (RONW) was 26% as of December 2025, reflecting efficient capital utilization. R&D expenditure remained consistent at around 5% of total revenue. The effective tax rate for the nine-month period was 23%, expected to remain similar for the full year. Capital expenditure for 9M FY26 was ₹235 crore, with a full-year guidance of ₹300 crore, including investments in a new liquid line manufacturing facility at Pithampur.

Management acknowledged the impact of the new Labour Code, accounting for an incremental liability of ₹7 crore in Q3 FY26. They also addressed the Income Tax Authorities' search operations in August 2025, noting no formal communication or adjustments made to the financial results yet. The overall tone of the management commentary was balanced, acknowledging challenges while emphasizing strategic focus and confidence in future growth. Ajanta Pharma's Q3 FY26 performance underscores its strategic clarity and disciplined execution, positioning it for sustained growth in a dynamic pharmaceutical landscape.